555 results about "Prostate cancer" patented technology

The invention discloses a prostate cancer three-classification risk layering method based on an integrated learning model, and relates to the technical field of data processing and analysis. The method comprises the following steps: collecting clinical information and pathological data of a patient with increased PSA, and dividing the data into a training set and a test set; the training set is preprocessed, and prediction features are screened through LASSO regression; constructing a plurality of machine learning base models based on the features, and training and optimizing through cross validation; soft voting is constructed through an integration strategy, and an integration model is stacked; setting double thresholds according to the integrated model prediction probability, and establishing a layering rule; combining an integrated model and rules to form a three-classification model, and judging low, high and medium risks according to probabilities; and finally verifying the model diagnosis performance in the test set. According to the method, through cross-modal feature integration and ensemble learning, the method is PSAlt; accurate risk stratification is provided for 30 ng / mL people, biopsy decision-making efficiency is optimized, and excessive puncture and missed diagnosis risks are reduced.

The invention discloses a prostate cancer endocrine therapy drug resistance prediction system based on multi-model artificial intelligence. The prostate cancer endocrine therapy drug resistance prediction system comprises a data acquisition and preprocessing module, a single omics prediction module, a multi-modal feature integration module, a model training module and a prediction result output module. Multi-omics data of a patient is collected and preprocessed, data representations of omics data of different labels are generated by using priori knowledge, and an optimal single-omics prediction model is matched for the omics data of different labels based on the data representations after knowledge enhancement. And constructing a multi-omics prediction model of the prostatic cancer endocrine treatment drug resistance by using the optimal single-omics prediction model corresponding to the different label medical data by adopting Stacking, predicting the drug resistance risk of the patient within a preset time, outputting an early warning, and adjusting the treatment scheme of the patient according to the drug resistance risk. According to the method, the multi-omics data are integrated, the accurate multi-omics prediction model for the drug resistance of the endocrine therapy of the prostate cancer is constructed, and the accuracy and clinical applicability of drug resistance prediction are improved.

The invention provides a prostate cancer multi-modal data federal learning method and system, and relates to the technical field of intelligent medical treatment and distributed artificial intelligence cross, and the method comprises the steps: selecting a plurality of key feature regions in a feature space as a reference basis based on updated global feature parameters, and constructing a feature distribution topological structure; performing partition division on the feature distribution topological structure to generate a plurality of feature subspaces; calculating a spatial characteristic index according to the characteristic density and the distribution characteristic of each characteristic subspace, and generating a weight adjustment coefficient based on the spatial characteristic index; and dynamically optimizing the updated global feature parameters by using the weight adjustment coefficient to obtain optimized federal learning model parameters. Through multi-modal data feature alignment, gradient compression transmission, global gradient aggregation and parameter dynamic optimization, a complete prostate cancer multi-modal data federated learning framework is constructed, and model performance and cross-mechanism cooperation efficiency are improved.

The invention belongs to the technical field of medical image processing, and particularly relates to a multimodal prostate cancer detection method fusing a memory mechanism and a space Transform, which comprises the following steps: constructing a multimodal prostate cancer detection network, and realizing prostate cancer detection through the multimodal prostate cancer detection network; according to the method, a Triad structured path is designed, efficient cooperation and guide fusion of multi-modal information is realized through division cooperation of dominant, auxiliary and control modalities, an encoder adopts a Swinin-Unet architecture, a window attention mechanism is combined, local details are kept, and meanwhile, the global modeling capability is enhanced; a dynamic memory unit DMU is further introduced, historical features are fused, a space gating mechanism is introduced, and the consistency and continuity of semantic expression are enhanced; in the decoding stage, an MESTrans module is embedded, and semantic alignment and boundary enhancement between modals are realized under multiple scales.

The invention relates to the technical field of computers, and discloses an automatic segmentation and intelligent plan generation method and device suitable for self-adaptive radiotherapy of prostate cancer. Comprising the following steps: acquiring medical image data of a treated object, clinical dose data of a target area and an organ at risk in a focus area of the treated object, and clinical treatment data of a preset priority level; performing automatic segmentation based on the medical image data to obtain target segmentation data; performing dose distribution prediction according to the target segmentation data to obtain initial dose distribution data, and performing iterative optimization on the initial dose distribution data by using clinical treatment data to obtain target dose distribution data of the treated object; and performing iterative optimization of a radiotherapy plan based on the target dose distribution data, and generating a target radiotherapy plan of the treated object. Therefore, on the basis of realizing accurate, efficient and automatic segmentation of the prostate cancer target region and the endangered organ, multi-round iterative optimization of dose distribution and the radiotherapy plan is carried out, and finally a high-quality target radiotherapy plan is obtained.

The present invention relates to a hetero (aromatic) ring-substituted cyclic diamine compound, the preparation thereof and the use thereof in the preparation of a drug for treating and / or preventing tumors. The structural formula of the compound is as shown in (I). The compound has a significant inhibitory effect on the growth of cells of tumors such as leukemia, lymphoma, breast cancer, melanoma, ovarian cancer, colorectal cancer, cervical cancer, lung cancer, prostate cancer, esophageal cancer, glioma, kidney cancer, nasopharyngeal carcinoma, liver cancer, gastric cancer and pancreatic cancer. Compared with the prior art, the compound of the present invention has a broad-spectrum anti-tumor activity, has a good effect on inhibiting tumors, and has an effect of degrading PD-L1 proteins, and is thus a PD-L1 immunomodulator.

The invention provides a prostate cancer biochemical recurrence prediction system based on pathological sections and a construction method. Based on a high-definition panoramic pathological section scanning image of a pathological section after a radical operation, a multi-instance algorithm based on a cyclic cross attention module and a pseudo-packet strategy is adopted, deep features of tumor images with different objective lens multiples are extracted firstly, and then feature representation of a panoramic pathological section scanning image level is generated in a weak supervision network; postoperative biochemical recurrence risk prediction results under different multiples are obtained; and then integrating model results under different scales, and predicting whether the patient finally has biochemical recurrence or not through multi-center verification. According to the system, multi-center, multi-slice and multi-scale panoramic pathological section scanning images are creatively used for training and verification, the risk of prostate cancer recurrence of a patient is predicted through pathological sections after radical treatment, the risk of recurrence of the patient within 3 years and longer time after the radical treatment is accurately predicted, and more personalized treatment is achieved.

Disclosed herein are methods of treating androgen-dependent cancers, including androgen dependent prostate cancer.

A biomimetic nano immunosubstrate material, a preparation method therefor and a use thereof. The biomimetic nano immunosubstrate material comprises a PDMS@AgNPs@ZIF-67 biomimetic immunosubstrate and a gold nanorod immunoprobe. The preparation method comprises the following steps: (S10) preparing a ZIF-67 nanomaterial; (S20) preparing a PDMS@AgNPs@ZIF-67 biomimetic polymeric material; (S30) preparing a PDMS@AgNPs@ZIF-67 biomimetic immunosubstrate material; and (S40) synthesizing a gold nanorod immunoprobe. A SERS substrate having both a synergistic enhancement effect and a molecular anchoring capability is constructed on a MOFs-modified biomimetic substrate, thereby improving the efficiency and sensitivity of prostate cancer tests.

The invention belongs to the field of chemical medicines, and particularly relates to a combined medicine for preventing and / or treating prostatic cancer, application of the combined medicine and a medicine composition. The combined medicine disclosed by the invention comprises immune cells with enhanced infiltration degree and a galectin-1 inhibitor; the immune cells with enhanced infiltration degree are natural killer (NK) cells with TTTY15-USP9Y chimera RNA knocked out, the infiltration degree and anti-tumor activity of the NK cells in a prostate cancer microenvironment can be improved, and the activated NK cells have a stronger killing effect on tumor cells in vitro. The immune cells with enhanced infiltration degree and the galectin-1 inhibitor are combined for use, so that the composition shows a synergistic effect in treatment of prostatic cancer, and has a wide application prospect.

The invention provides a group of marker combinations related to the prostatic cancer, wherein the marker combinations comprise hsa-miR-12125, hsa-miR-21, hsa-miR-103 and hsa-miR-9903, and the application of the marker combinations in preparation of a prostatic cancer detection reagent and a prostatic cancer treatment medicine is researched and developed at the same time. The prostate cancer detection reagent provided by the invention comprises specific primers designed for the four markers, has high sensitivity and specificity, and improves the accuracy of prostate cancer diagnosis by jointly detecting and diagnosing the prostate cancer through the four markers. The medicine for treating the prostatic cancer, provided by the invention, comprises an hsa-miR-12125 inhibitor, an hsa-miR-21 inhibitor, an hsa-miR-103 analogue and an hsa-miR-9903 analogue, and can be used for effectively inhibiting the occurrence and development of the prostatic cancer.

The present invention relates to methods of treating prostate cancer in a subject in need thereof, comprising administering a therapeutically effective amount of a KLK2xCD3 bispecific antibody or bispecific binding fragment thereof to the subject to treat the prostate cancer.

The invention discloses an ROS-responsive prostate cancer targeting prodrug as well as a preparation method and application thereof, and belongs to the technical field of biological medicines. The prodrug is formed by covalently linking a prostate cancer targeting peptide SYEELR, a ROS (reactive oxygen species) response type ketal thiol (TK) connexon and an active molecule Devimistat. The preparation method comprises the following two steps: firstly, coupling Devimistat with a TK linker to obtain an intermediate Dev-TK, and then coupling the intermediate Dev-TK with an SYEELR peptide fragment to obtain a target product. The prodrug can specifically break and release Devimistat in a tumor high active oxygen microenvironment, and active targeting delivery is realized by virtue of the SYEELR peptide. The invention provides a novel prostatic cancer treatment strategy with accurate targeting, controllable release, enhanced curative effect and toxicity reduction potential.

The present provides a method of treating ovarian cancer, breast cancer, gastrointestinal cancer, lung cancer, cancer of the brain or prostate cancer in a subject in need thereof, comprising administering to the subject a first amount of a selective PARP1 inhibitor or a pharmaceutically acceptable salt thereof, and a second amount of an ATR inhibitor or a pharmaceutically acceptable salt thereof. Also disclosed are compositions and kits comprising a PARP inhibitor and ATR inhibitor.

The present invention relates to methods, systems and kits for the diagnosis, prognosis and the determination of cancer progression of prostate cancer in a subject. The invention also provides clinically useful genomic classifiers for predicting prostate cancer metastasis and identifying tumor aggressiveness. The methods, systems and kits can provide expression-based analysis of biomarkers for purposes of predicting metastatic disease and lethal prostate cancer in a subject. Further disclosed herein, in certain instances, are probe sets for use in predicting prostate cancer metastasis in a subject. Classifiers for predicting prostate cancer metastasis are provided. Methods of treating cancer based on tumor aggressiveness are also provided. The methods and classifiers of the present invention are also useful for predicting early prostate cancer metastasis.

The present disclosure provides a high-energy, low toxicity radiopharmaceutical composition comprising actinium that performs as an anti-tumor agent for targeted radionuclide therapy and has improved shelf-life stability. Specifically, the radiopharmaceutical composition may include 225Ac-PSMA I&T, sodium ascorbate, and optionally hydrochloric acid. The radiopharmaceutical composition may be suitable for administration to a patient in need thereof, such as for the purpose of treating prostate cancer.

The invention belongs to the technical field of medicines, and provides a preparation technology of a sterile injection of rerugolix, which comprises the following steps: redissolving freeze-dried powder consisting of raw material medicines and auxiliary materials by using sterile water for injection, slowly releasing the rerugolix within 2-8 weeks, maintaining the dynamic balance of blood concentration, and preparing the sterile injection of the rerugolix by using the freeze-dried powder to prepare the sterile injection of the rerugolix. Release of gonadotropin is effectively controlled, and the pharmaceutical composition is used for treating indications such as prostatic cancer, uterine fibroma and endometriosis.

The invention provides an organoid chip for screening micro-ecological drugs as well as application and a preparation method of the organoid chip, and relates to the technical field of biological medicines. The invention provides a chip integrating intestinal epithelium, a prostate cancer organ and a bladder cancer organ, which is used for researching how microecological preparations, such as probiotics, metabolites and the like, affect tumor microenvironment and immunotherapy effects. The chip can simulate interaction of intestinal tract-tumor axis, and provides an in-vitro evaluation system for precise tumor immunotherapy.

The present disclosure relates to novel deuterated retinoidal compounds and methods of preparing the deuterated retinoidal compounds. The present disclosure also provides pharmaceutical compositions including the deuterated retinoidal compounds, and uses of the deuterated retinoidal compounds to treat diseases including breast and prostate cancers.

The invention relates to a hetero (aromatic) ring substituted cyclic diamine compound, preparation thereof and application of the hetero (aromatic) ring substituted cyclic diamine compound in preparation of drugs for treating and / or preventing tumors. The structural formula of the compound is shown as (I). The compound has an obvious growth inhibition effect on tumor cells of leukemia, lymphoma, breast cancer, melanoma, ovarian cancer, colorectal cancer, cervical cancer, lung cancer, prostate cancer, esophagus cancer, glioma, kidney cancer, nasopharynx cancer, liver cancer, stomach cancer, pancreatic cancer and the like. The compound disclosed by the invention has broad-spectrum anti-tumor activity; the compound has a good tumor inhibition effect and a PD-L1 protein degradation effect, and is a PD-L1 immunomodulator.

Small molecule radiohalogenated PSMA inhibitors and metal complexes thereof and their use in radioimaging and radiotherapy for treating PSMA-related diseases, including prostate cancer, are disclosed. The combination of small molecule radiohalogenated PSMA inhibitors with a competitive PSMA ligand for reducing off-target accumulation of the radiohalogenated PSMA inhibitor also is disclosed.

The present disclosure includes methods, pharmaceutical compositions, and kits for the treatment of prostate cancer, wherein AZD5305 and darolutamide are dosed in combination to a subject in need.

The present disclosure includes methods, pharmaceutical compositions, and kits for the treatment of prostate cancer, wherein AZD5305 and enzalutamide are dosed in combination to a subject in need.

This invention relates to talazoparib, or a pharmaceutically acceptable salt thereof, in combination with enzalutamide, or a pharmaceutically acceptable salt thereof, for the treatment of homologous recombination repair (HRR) gene-mutated metastatic castration-resistant prostate cancer and methods of increasing overall survival thereof.

The invention relates to a model privacy processing method based on model pruning and a prostate cancer early warning method. The method comprises the following steps: acquiring a sample data set; performing first training on the initial first network model through the sample data set to obtain the first network model after the first training and importance parameters of each neuron in the first network model; the initial first network model is trained for the second time through the sample data set, the first network model after the second time of training is obtained, and the loss functions of the first time of training and the second time of training are different; performing model pruning processing based on the importance parameters of each neuron, the first network model after the first training and the first network model after the second training to obtain a second network model; configuring homomorphic encryption parameters based on the public key; and based on the homomorphic encryption parameter, performing privacy processing on the model component of the second network model to obtain a target network model. According to the scheme of the embodiment, model processing efficiency and safety can be considered.

The invention described herein provides biological markers for the diagnosis, prognosis, and monitoring of prostate cancer.

The invention belongs to the field of medicines, and particularly relates to a nanosheet capable of activating an STING pathway and improving microwave ablation as well as a preparation method and application of the nanosheet. The nanosheet is prepared from MXenes through organic acid treatment, organic alkali dispersion, STING agonist compounding and phospholipid modification, and has good microwave thermal conversion efficiency and an STING pathway activation function. The combined microwave ablation can enhance the immunogenic death of tumor cells, promote the maturation of dendritic cells, doubly activate immune response and effectively inhibit the growth and metastasis of prostatic cancer, provides a new strategy for the treatment of prostatic cancer, and can be used for preparing drugs for treating prostatic cancer.

The invention belongs to the field of organic synthesis and medicinal chemistry, and particularly provides an efficient synthesis method of an N, N-diphenyl aniline compound based on a naphtho-indolizino-phenothiazine skeleton and anti-tumor application of the N, N-diphenyl aniline compound based on the naphtho-indolizino-phenothiazine skeleton. Through Suzuki reaction, functional coupling based on a naphtho-indolizino-phenothiazine skeleton and an N, N-diphenyl aniline group is realized for the first time. In-vitro anti-tumor evaluation shows that the compound has remarkable inhibitory activity on various human tumor cells, especially has the strongest effect on breast cancer MCF-7 cells (IC50 = 0.15 mu M), and the activity is improved by 266 times compared with that of cis-platinum; prostate cancer PC-3, liver cancer HepG2, lung adenocarcinoma A549 and cervical cancer Hela cells are also remarkably inhibited. The toxicity to normal umbilical vein endothelial cells (HUVEC) is far lower than that of tumor cells, and the selectivity is excellent. The research provides a lead compound with great potential for developing high-efficiency and low-toxicity targeted anti-tumor drugs.

The application discloses application of a naphthalene nitrile derivative in preparation of an antitumor pharmaceutical composition, in particular, application of a 2-(imino)-naphthalene nitrile derivative in preparation of an antitumor pharmaceutical composition. The 2-(imino)-naphthalene nitrile derivative provided by the application has a significant inhibiting effect on colon cancer, liver cancer, lung cancer, prostate cancer, cervical cancer, neuroglioma and breast cancer, exhibits excellent antitumor characteristics, can be used as a leading drug molecule for resisting tumors, and has a good development and application prospect in development of antitumor drugs.

The present disclosure relates to methods of treating PTEN-deficient metastatic hormone- sensitive prostate cancer (mHSPC) in patients in need thereof, the methods comprising administering to the patients a combination comprising capivasertib or a pharmaceutically acceptable salt thereof; and abiraterone or an ester prodrug thereof, or a pharmaceutically acceptable salt thereof.